News articles about Cardiovascular Systems (NASDAQ:CSII) have trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cardiovascular Systems earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 46.3446198746525 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Cardiovascular Systems (NASDAQ:CSII) traded up $0.13 during trading on Friday, reaching $23.73. 192,500 shares of the company’s stock were exchanged, compared to its average volume of 275,199. The firm has a market capitalization of $805.27, a P/E ratio of 1,180.00 and a beta of 2.53. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.30 and a quick ratio of 3.47. Cardiovascular Systems has a 12-month low of $23.00 and a 12-month high of $33.11.
Cardiovascular Systems (NASDAQ:CSII) last posted its earnings results on Wednesday, October 25th. The medical device company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $49.70 million during the quarter, compared to analysts’ expectations of $51.00 million. Cardiovascular Systems had a negative net margin of 0.93% and a positive return on equity of 0.74%. The business’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.06) earnings per share. research analysts forecast that Cardiovascular Systems will post -0.05 earnings per share for the current year.
CSII has been the topic of a number of analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $37.00 price objective (up from $32.00) on shares of Cardiovascular Systems in a research note on Friday, July 14th. Citigroup Inc. initiated coverage on shares of Cardiovascular Systems in a research note on Thursday, September 21st. They set a “market perform” rating on the stock. Zacks Investment Research downgraded shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Raymond James Financial, Inc. initiated coverage on shares of Cardiovascular Systems in a research note on Friday, September 22nd. They set a “market perform” rating on the stock. Finally, BidaskClub downgraded shares of Cardiovascular Systems from a “sell” rating to a “strong sell” rating in a research note on Friday, August 18th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $35.33.
TRADEMARK VIOLATION WARNING: “Cardiovascular Systems (CSII) Receives Media Sentiment Rating of 0.14” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/11/cardiovascular-systems-csii-receives-media-sentiment-rating-of-0-14.html.
In other news, Director Edward M. Brown sold 13,031 shares of the stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $29.09, for a total value of $379,071.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Laurence L. Betterley sold 4,443 shares of the stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $30.74, for a total transaction of $136,577.82. Following the completion of the transaction, the chief financial officer now directly owns 223,557 shares of the company’s stock, valued at approximately $6,872,142.18. The disclosure for this sale can be found here. Insiders sold 51,065 shares of company stock valued at $1,514,031 in the last three months. Company insiders own 3.30% of the company’s stock.
About Cardiovascular Systems
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.